A Keech, D Colquhoun, J Best, A Kirby, RJ … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—In patients allocated to placebo, the risk of a major CHD event was
61% higher in patients with diabetes and 23% higher in the IFG group than in
patients with normal fasting glucose, and the risk of any cardiovascular ... Cited by 136 - Related articles - BL Direct - All 5 versions
FD Care - Diabetes Care, 2003 - medscape.com Diabetes is the most common endocrine disorder worldwide, with an estimated
prevalence of 140 million adults in 1997. [1] As many adults have an elevated
fasting glucose level, or impaired fasting glucose (IFG), [2,3] which is ... Related articles - All 7 versions
- ►diabetesjournals.org [PDF] NR Poulter, PS Sever, B Dahlof, H Wedel… - Diabetes Care, 2005 - Am Diabetes Assoc Glial cell line–derived neurotrophic factor (GDNF) belongs to the neu-
rotrophic factor family. GDNF functions are not restricted to neurons but are
also implicated in glial cell develop- ment (1). We observed high ... Cited by 171 - Related articles - BL Direct - All 12 versions
- ►ahajournals.org RB Goldberg, MJ Mellies, FM Sacks, LA Moye … - Circulation, 1998 - Am Heart Assoc Methods and Results—The Cholesterol And Recurrent Events (CARE) trial, a
5-year trial that compared the effect of pravastatin and placebo, included 586
patients (14.1%) with clinical diagnoses of diabetes. The participants with ... Cited by 779 - Related articles - BL Direct - All 6 versions
- ►dm2nb.ca [PDF] SM Haffner, CM Alexander, TJ Cook, SJ … - Archives of Internal Medicine, 1999 - archinte.highwire.org You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 385 - Related articles - BL Direct - All 7 versions
R Collins, J Armitage, S Parish, P Sleigh, R … - Lancet, 2003 - ncbi.nlm.nih.gov BACKGROUND: Individuals with diabetes are at increased risk of cardiovascular
morbidity and mortality, although typically their plasma concentrations of LDL
cholesterol are similar to those in the general population. Previous ... Cited by 726 - Related articles - All 7 versions
HB Rubins, SJ Robins, D Collins, DB Nelson, … - Archives of Internal Medicine, 2002 - archinte.highwire.org You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 451 - Related articles - BL Direct - All 5 versions
VG Athyros, AA Papageorgiou, VV Athyrou, … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 120 consecutive patients, who were free
of coronary artery disease (CAD) at entry, were studied for a period of 24
weeks. These patients were randomly assigned to atorvastatin (20 mg/day, n ... Cited by 176 - Related articles - BL Direct - All 8 versions
- ►mt.gov [PDF] HM Colhoun, DJ Betteridge, PN Durrington, … - The Lancet, 2004 - Elsevier 2838 patients aged 40–75 years in 132 centres in the UK and Ireland were
randomised to placebo (n=1410) or atorvastatin 10 mg daily (n=1428). Study
entrants had no documented previous history of cardiovascular disease, an ... Cited by 1270 - Related articles - All 43 versions
- ►diabetesjournals.org J Shepherd, P Barter, R Carmena, P Deedwania … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—End-of-treatment mean LDL cholesterol levels were 98.6 mg/dl with
atorvastatin 10 mg and 77.0 mg/dl with atorvastatin 80 mg. A primary event
occurred in 135 patients (17.9%) receiving atorvastatin 10 mg, compared ... Cited by 135 - Related articles - BL Direct - All 6 versions
